Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03285607
Title MCS110 Combined With Neoadjuvant Doxorubicin, Cyclophosphamide, and Weekly Paclitaxel in Patients With Hormone-Receptor Positive and HER2- Breast Cancer
Recruitment Withdrawn
Gender
Phase Phase I
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

Her2-receptor negative breast cancer

Therapies

Cyclophosphamide + Doxorubicin + MCS110 + Paclitaxel

Age Groups: adult | senior
Covered Countries


No variant requirements are available.